GlassScriptPhysician profile
Holly S Glover
NPI 1508104589
$418,311.83
in general payments reported to CMS, 2019-2025
33 companies · $753 in 2025
The $753 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $73K · 2023: $220K · 2024: $109K · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Consulting Fee: $43K · Travel and Lodging: $32K · Food and Beverage: $20K · Honoraria: $550 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $233,572.00 |
| Consulting Fee | $43,479.82 |
| Travel and Lodging | $31,654.30 |
| Food and Beverage | $20,340.87 |
| Honoraria | $550.00 |
| Education | $344.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $148,800.66 | 2021-2025 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $107,448.66 | 2022-2024 | Vtama, Tapinarof |
| Galderma Laboratories, L.P. | $44,987.84 | 2021-2023 | Aklief, Epsolay, Oracea |
| Leo Pharma INC. | $44,228.65 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $35,731.24 | 2021-2024 | Sotyktu |
| Incyte Corporation | $6,772.05 | 2022-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $5,559.79 | 2023 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $5,099.55 | 2021-2024 | Dupixent |
| Genzyme Corporation | $3,783.69 | 2021-2024 | |
| Pfizer INC. | $3,512.51 | 2021-2024 | |
| Abbvie INC. | $3,222.66 | 2021-2024 | |
| Ucb, INC. | $2,169.70 | 2021-2024 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $1,229.93 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $1,228.26 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,195.86 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $750.00 | 2023 | Xolair |
| Mayne Pharma Commercial LLC | $649.85 | 2021-2023 | |
| Janssen Biotech, INC. | $632.19 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Journey Medical Corporation | $385.69 | 2022-2023 | |
| Amgen INC. | $321.68 | 2022-2024 | Otezla |
| Vyne Pharmaceuticals INC. | $117.09 | 2021 | |
| Epi Health, LLC | $108.33 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $98.88 | 2023-2024 | Siliq, Arazlo, Cabtreo |
| Celgene Corporation | $65.50 | 2022-2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.72 | 2022-2023 | Spevigo |
| Biofrontera INC. | $35.68 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $27.78 | 2022 | |
| Almirall LLC | $26.93 | 2022-2023 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $18.97 | 2022 | |
| Acclarent, INC | $18.85 | 2022 | |
| Nabriva Therapeutics, Plc | $18.21 | 2021 | |
| Dermira, INC. | $12.60 | 2021 | |
| Misonix INC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.